Step by Step


ABIM MOC Activity ID

1/23/2018 - Medical Grand Rounds: Strategies to Enhance the Efficacy of CAR T Cells





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the principles of synthetic biology in T cell therapy of cancer.
  • Discuss safety and efficacy of chimeric antigen receptor modified T cells for B cell malignancies.
  • Define the mechanisms of tumor escape from T cell immunotherapies

Stanley Riddell, MD — Fred Hutchinson Cancer Research Center, University of Washington American Cancer Society Virginia Hobbs Charitable Trust Research Professor
Dr. Riddell receives grant/research support from Juno Therapeutics. He is consultant for Juno Therapeutics, Adaptive Biotechnologies, Cell Medica, NOHLA. He is a stockholder in Juno Theapeutics.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.